Azactam

Osteomyelitis, Gonorrhea, Septicemia + 11 more
Treatment
11 FDA approvals
18 Active Studies for Azactam

What is Azactam

AztreonamThe Generic name of this drug
Treatment SummaryCiprofloxacin is an antibiotic used to treat infections caused by certain types of bacteria. It is especially effective against gram-negative bacteria, which are commonly found in the meninges, bladder, and kidneys. However, it can cause an overgrowth of gram-positive bacteria, which can lead to a secondary infection.
Azactamis the brand name
Azactam Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Azactam
Aztreonam
2009
15

Approved as Treatment by the FDA

Aztreonam, commonly known as Azactam, is approved by the FDA for 11 uses which include Communicable Diseases and Communicable Diseases .
Communicable Diseases
Communicable Diseases
Gram-Negative Bacterial Infections
Skin Infections
Septicemia
Abdominal Infection
Gynaecological infection
Lower Respiratory Tract Infection (LRTI)
Intraabdominal Infections
Urinary Tract Infections
Bronchitis

Effectiveness

How Azactam Affects PatientsAztreonam is an antibiotic used to treat infections caused by certain types of bacteria, like Pseudomonas aeruginosa. It is sometimes called the "magic bullet" for aerobic gram-negative bacteria because it is very effective against them. Unlike other antibiotics, it does not get broken down by beta-lactamases (enzymes produced by some bacteria), so it can be used to treat infections that are resistant to other antibiotics. It works in a wide range of pH levels and can also stay active in the presence of human serum and without oxygen.
How Azactam works in the bodyAztreonam stops bacteria from making the cell walls they need to survive. It does this by attaching itself to a protein found in bacteria called penicillin binding protein 3 (PBP3). By binding to this protein, aztreonam prevents the third and final stage of cell wall synthesis. Bacteria then die as their own enzymes break down their cell walls. Aztreonam may also interfere with an enzyme that prevents bacteria from being destroyed.

When to interrupt dosage

Condition
Dosage
Administration
Bronchitis
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Intravenous, , Injection, solution, Injection, solution - Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Respiratory (inhalation), Solution - Respiratory (inhalation), Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution - Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution
Cystic Fibrosis
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Intravenous, , Injection, solution, Injection, solution - Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Respiratory (inhalation), Solution - Respiratory (inhalation), Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution - Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution
Pseudomonas Infections
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Intravenous, , Injection, solution, Injection, solution - Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Respiratory (inhalation), Solution - Respiratory (inhalation), Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution - Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution
Communicable Diseases
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Intravenous, , Injection, solution, Injection, solution - Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Respiratory (inhalation), Solution - Respiratory (inhalation), Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution - Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution
Communicable Diseases
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Intravenous, , Injection, solution, Injection, solution - Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Respiratory (inhalation), Solution - Respiratory (inhalation), Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution - Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution
Febrile Neutropenia
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Intravenous, , Injection, solution, Injection, solution - Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Respiratory (inhalation), Solution - Respiratory (inhalation), Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution - Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution
Osteomyelitis
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Intravenous, , Injection, solution, Injection, solution - Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Respiratory (inhalation), Solution - Respiratory (inhalation), Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution - Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution
Intraabdominal Infections
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Intravenous, , Injection, solution, Injection, solution - Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Respiratory (inhalation), Solution - Respiratory (inhalation), Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution - Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution
Septicemia
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Intravenous, , Injection, solution, Injection, solution - Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Respiratory (inhalation), Solution - Respiratory (inhalation), Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution - Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution
Urinary Tract Infections
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Intravenous, , Injection, solution, Injection, solution - Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Respiratory (inhalation), Solution - Respiratory (inhalation), Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution - Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution
Gonorrhea
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Intravenous, , Injection, solution, Injection, solution - Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Respiratory (inhalation), Solution - Respiratory (inhalation), Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution - Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution
Gram-Negative Bacterial Infections
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Intravenous, , Injection, solution, Injection, solution - Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Respiratory (inhalation), Solution - Respiratory (inhalation), Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution - Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution
Arthritis, Infectious
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Intravenous, , Injection, solution, Injection, solution - Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Respiratory (inhalation), Solution - Respiratory (inhalation), Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution - Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution
Osteomyelitis
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Intravenous, , Injection, solution, Injection, solution - Intravenous, Injection, powder, for solution, Intramuscular; Intravenous, Respiratory (inhalation), Solution - Respiratory (inhalation), Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution - Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution

Warnings

There are 20 known major drug interactions with Azactam.
Common Azactam Drug Interactions
Drug Name
Risk Level
Description
Vibrio cholerae CVD 103-HgR strain live antigen
Major
The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Aztreonam.
Abacavir
Minor
Aztreonam may decrease the excretion rate of Abacavir which could result in a higher serum level.
Aclidinium
Minor
Aztreonam may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine
Minor
Aztreonam may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Albutrepenonacog alfa
Minor
Aztreonam may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
image of a doctor in a lab doing drug, clinical research

Azactam Novel Uses: Which Conditions Have a Clinical Trial Featuring Azactam?

33 active clinical trials are currently in progress to assess the potential of Azactam to reduce Bone and Joint Infections, Cystic Fibrosis (CF) and Gram-Negative Bacterial Infections.
Condition
Clinical Trials
Trial Phases
Septicemia
1 Actively Recruiting
Not Applicable
Gram-Negative Bacterial Infections
0 Actively Recruiting
Cystic Fibrosis
0 Actively Recruiting
Urinary Tract Infections
7 Actively Recruiting
Not Applicable, Phase 4
Communicable Diseases
0 Actively Recruiting
Osteomyelitis
0 Actively Recruiting
Intraabdominal Infections
1 Actively Recruiting
Not Applicable
Arthritis, Infectious
0 Actively Recruiting
Communicable Diseases
0 Actively Recruiting
Bronchitis
2 Actively Recruiting
Not Applicable
Febrile Neutropenia
3 Actively Recruiting
Phase 2, Not Applicable
Gonorrhea
0 Actively Recruiting
Osteomyelitis
4 Actively Recruiting
Phase 4, Phase 2, Not Applicable
Pseudomonas Infections
0 Actively Recruiting

Azactam Reviews: What are patients saying about Azactam?

2.7Patient Review
4/29/2013
Azactam for Infection of Female Pelvic Organs caused by Klebsiella
It worked similarly to Gentamycin, clearing my infection within a few days.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about azactam

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Azactam a penicillin?

"Aztreonam is an antibiotic that was approved in 1986 for the treatment of Gram-negative bacterial infections via intravenous or intramuscular injection (Azactam®). This drug was marketed to treat bacterial infections and is safe for patients with penicillin allergies."

Answered by AI

What is Azactam used for?

"AZACTAM is used to treat serious bacterial infections. It may be used to treat infections in different parts of the body and is sometimes given with other antibiotics. Your doctor may have prescribed AZACTAM for another purpose."

Answered by AI

What bacteria does Azactam cover?

"Aztreonam is an antibiotic that is used to treat infections caused by bacteria. This includes infections of the bones, endometritis, intra abdominal infections, pneumonia, urinary tract infections, and sepsis."

Answered by AI

What class of antibiotic is Azactam?

"This medication belongs to a class of drugs called Monobactams. It is not known if it is safe and effective in children younger than 9 months of age."

Answered by AI

Clinical Trials for Azactam

Image of Baylor College of Medicine in Houston, United States.

Educational Tool for Urinary Tract Infections

18+
All Sexes
Houston, TX
Urine culture is the most common microbiological test in the outpatient setting in the United States. Unfortunately, contamination during collection is prevalent and undermines test accuracy, leading to incorrect diagnosis, unnecessary treatment, wasted laboratory resources, and inflated costs. Unnecessary antibiotic treatment increases the risk of developing antimicrobial resistance, one of the most serious threats to patients and public health. The goal of this clinical trial is to test whether a bilingual (English and Spanish) educational intervention, an animated video and pictorial flyer, can reduce urine culture contamination and associated inappropriate antibiotic use in adult patients visiting safety-net primary care clinics. The main questions it aims to answer are: 1. Does providing patients with a bilingual educational intervention reduce urine culture contamination rates? 2. Does the intervention lead to fewer unnecessary urinary antibiotic prescriptions? 3. Does providing patients with a bilingual educational intervention reduce contaminated urinalyses? Researchers will compare patients randomized to receive the educational intervention (video and flyer) to those receiving usual care to see if the intervention improves urine collection accuracy and reduces inappropriate antibiotic use. Participants will watch a short, animated video with step-by-step instructions for proper midstream clean-catch urine (MSCC) collection, receive a pictorial flyer (with stills from the video) reinforcing the instructions, and provide a urine sample for culture. For our hypothesis, patients who receive the educational intervention will have: lower urine culture contamination rates (primary outcome), fewer urinary antibiotic prescriptions (secondary outcome), and fewer contaminated urinalyses (secondary outcome). The objectives are to (1) develop educational tools: Create an animated video and pictorial flyer with step-by-step urine collection instructions for women and men, developed through an iterative, stakeholder-engaged process, (2) assess acceptability: Use mixed methods (quantitative surveys and qualitative interviews) to evaluate and refine the tools for usability and cultural/linguistic appropriateness, and (3) test effectiveness: Conduct a randomized controlled trial to assess the intervention's impact on urine contamination rates, antibiotic prescribing, and patient satisfaction.
Waitlist Available
Has No Placebo
Baylor College of MedicineLarissa Grigoryan, MD, PhD
Image of UPMC Magee-Womens Hospital in Pittsburgh, United States.

Catheterization Methods for Postpartum Urinary Problems

18+
All Sexes
Pittsburgh, PA
At least ten percent of patients have postpartum urinary retention or difficulty urinating after birth, which can cause incontinence and other urinary problems long-term. After getting an epidural placed, patients should be numb in their pelvic region. This numbness makes it difficult to feel the need to urinate, so patients need a urinary catheter placed to empty the bladder. Some patients have one catheter placed throughout their labor and others have a catheter placed to empty the bladder then removed every few hours. The investigators are studying whether placing a catheter once or catheterizing multiple times affects the rate of postpartum urinary problems and infection.
Waitlist Available
Has No Placebo
UPMC Magee-Womens HospitalAnna Binstock, MD
Image of University of California, San Francisco in San Francisco, United States.

Trimethoprim-Sulfamethoxazole for Urinary Tract Infections

13 - 29
All Sexes
San Francisco, CA
The goal of this clinical trial is to learn if a common antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX) can help prevent urinary tract infections (UTIs) in children and young adults who recently had a kidney transplant. Most people take TMP-SMX for about 6 months after getting a kidney transplant. In this study, researchers want to see what happens if people keep taking it for 6 more months. The main questions this study is asking are: * Does TMP-SMX lower the number of UTIs in the first year after transplant? * What side effects or problems do participants have while taking TMP-SMX? Researchers will compare TMP-SMX to a placebo (a look-alike pill that does not contain any medication) to see if TMP-SMX works to prevent UTIs. Participants will: * Take either TMP-SMX or a placebo pill by mouth every day for 6 months * Have three visits to touch base with the study team about any issues * Complete short monthly online surveys about any symptoms or side effects * Share blood and urine test results from their regular transplant clinic visits
Phase 4
Waitlist Available
University of California, San FranciscoAlexandra Bicki, MD
Have you considered Azactam clinical trials? We made a collection of clinical trials featuring Azactam, we think they might fit your search criteria.Go to Trials
Image of Atlantic Health in Morristown, United States.

Methenamine for Urinary Tract Infection

18 - 100
Female
Morristown, NJ
Stress urinary incontinence (SUI) affects at least 40% of women in the United States. Synthetic polypropylene mid-urethral slings (MUS) are the gold standard treatment for SUI. Post-operative urinary tract infections (UTI) are one of the most common complications after MUS placement. Some studies have demonstrated that MUS placement can increase the risk of UTI up to 21-34%. Post-operative UTI can lead to significant healthcare and patient burden. This additional burden further contributes to an estimated annual cost of $1.6 billion for UTI management in the United States. With increased antibiotic usage, there is simultaneous increase in bacterial resistance leading to treatment refractory UTI. The investigators prescribe post-operative antibiotics prophylactically for 3 days after MUS placement with or without concurrent pelvic reconstructive surgery based on prior literature recommending post-operative prophylaxis. There is a greater emphasis on limiting antibiotic use given the trend of development of bacterial resistance. There are studies supporting alternatives such as methenamine for recurrent UTI prophylaxis treatment, but there are limited studies evaluating methenamine for UTI prophylaxis after MUS.
Recruiting
Has No Placebo
Atlantic Health
Image of Benioff Children's Hospital - Oakland in Oakland, United States.

Decision Support for Lower Respiratory Infections in Children

6 - 17
All Sexes
Oakland, CA
Eliminating inappropriate antibiotic use in pediatric lower respiratory tract infections (LRTI) is the central focus of this research. LRTIs (pneumonia, bronchiolitis, and infection-related exacerbations of asthma) account for nearly one-third of all emergency department (ED) visits and 40% of all infection-related hospitalizations in US children. LRTIs also account for more antibiotic use in children's hospitals than any other condition, despite most LRTIs being viral in nature. Inappropriate antibiotics are associated with substantial adverse effects. Accordingly, national guidelines strongly discourage routine antibiotic use for bronchiolitis and acute asthma and argue for significantly reducing antibiotic exposure (initiation, spectrum, and duration) in pneumonia. To address the problem of inappropriate antibiotic use, hospital-based antimicrobial stewardship programs (ASPs) are now common nationwide, and these programs have demonstrated effectiveness in some hospital settings. Unfortunately, traditional ASP approaches do not translate well to the fast-paced and unpredictable ED environment, and hospital-based ASP resources are finite and not always immediately available. Clinical decision support (CDS) embedded within the electronic health record (EHR) is a strategy that could address the ED antibiotic stewardship gap. Informed by a deep understanding of the key facilitators and barriers to using CDS to support appropriate antibiotic use in ED and hospital settings, the investigators have developed two stewardship-focused CDS interventions for pediatric LRTI. The overarching goal of this research is to rigorously evaluate the implementation and effectiveness of these CDS tools, alone and in combination, against usual care only in a pragmatic randomized clinical trial at 3 U.S. children's hospitals.
Recruiting
Has No Placebo
Benioff Children's Hospital - Oakland (+2 Sites)Derek J Williams, MD, MPH
Image of Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center in Cleveland, United States.

Alio Smart Patch Monitoring for Cancer Patients

18 - 65
All Sexes
Cleveland, OH
Undergoing cancer treatment comes with various risks and side effects. This clinical trial aims to reduce those risks and side effects through continuous monitoring of vital signs and blood levels. The goal is to see if potential side effects can be identified and treated sooner. During this study, participants will wear an Alio Smartpatchâ„¢. The Alio Smartpatchâ„¢ is a wireless remote monitoring system. This device will measure participants' vital signs and blood levels. Participants will also be asked to use continuous glucose monitors to measure their glucose levels. The data collected on each participant from these devices will be remotely monitored at all times by clinical staff at a company known as Quantify Remote Care. If a participant's results look like they are experiencing a side effect, the participant will be contacted immediately by Quantify Remote Care team. The Quantify Remote Care team will function as an extension of the participant's cancer clinical team and will relay any significant issues back to them. Quantify Health also provides dietary and mental health support as needed for all participants.
Recruiting
Has No Placebo
Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer CenterAlberto Montero, MD, MBA
Image of Ronald Reagan UCLA Medical Center in Los Angeles, United States.

Next Day Clinic for Patient Care

18+
All Sexes
Los Angeles, CA
The Next Day Clinic (NDC) is a quality improvement initiative that will be launched and operated by UCLA Health starting July 22, 2024. Its goals are to improve patient care and safety and to maximize cost effectiveness. The way it does this is by identifying patients in the ED who would normally be admitted for low-acuity conditions, and diverting them to a high-acuity clinic the following day called the NDC. This will help decompress the ED and the hospital, and allow for overall higher quality care. The Health System has partnered with UCLA's Healthcare Value Analytics and Solutions \[UVAS\] group which specializes in these types of program evaluations. The analysis conducted by the study team will be used to directly inform NDC operations, scaling, and future plans.
Recruiting
Has No Placebo
Ronald Reagan UCLA Medical Center
Have you considered Azactam clinical trials? We made a collection of clinical trials featuring Azactam, we think they might fit your search criteria.Go to Trials
Image of BayCare Health System in Clearwater, United States.

Machine Learning Monitoring for Clinical Deterioration

18+
All Sexes
Clearwater, FL
In this study, the investigators will deploy a software-based clinical decision support tool (eCARTv5) into the electronic health record (EHR) workflow of multiple hospital wards. eCART's algorithm is designed to analyze real-time EHR data, such as vitals and laboratory results, to identify which patients are at increased risk for clinical deterioration. The algorithm specifically predicts imminent death or the need for intensive care unit (ICU) transfer. Within the eCART interface, clinical teams are then directed toward standardized guidance to determine next steps in care for elevated-risk patients. The investigators hypothesize that implementing such a tool will be associated with a decrease in ventilator utilization, length of stay, and mortality for high-risk hospitalized adults.
Waitlist Available
Has No Placebo
BayCare Health System (+2 Sites)Dana P Edelson, MD, MSAgileMD, Inc.
Image of Alberta Health Services in Edmonton, Canada.

Short Antibiotic Treatment for Febrile Neutropenia

18+
All Sexes
Edmonton, Canada
Infections are a common complication in patients with cancer. They are a significant cause of complications and death in this population. Patients with cancer and low neutrophil counts due to chemotherapy or disease often have a fever and receive antibiotic treatment. The optimal duration of this treatment is largely unknown. Late, there have been some data suggesting the safety of early discontinuation of antibiotics, though most centers still give more prolonged antibiotic therapies in this situation. The unnecessary prolonged antibiotic use may increase infections with multi-drug-resistant bacteria, which carry a high death rate. Also, an increase in infections caused by Clostridioides difficile and an increase in fungal infections can happen. However, some are concerned that stopping antibiotics while the neutrophil count is still low will result in life-threatening infections. Our study aims to test whether shorter antibiotic treatment in these situations is as safe as more prolonged treatment, resulting in better antibiotic prescription practices in this population.
Recruiting
Has No Placebo
Alberta Health Services (+3 Sites)Shahid Husain, MD
Have you considered Azactam clinical trials? We made a collection of clinical trials featuring Azactam, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security